UCB's Cimzia(R), The Only PEGylated Anti-TNF, Approved In Europe

Main Category: Arthritis / Rheumatology
Also Included In: Regulatory Affairs / Drug Approvals
Article Date: 08 Oct 2009 - 1:00 PDT

email to a friend

printer friendly

opinions

Current Article Ratings:

Patient / Public:
Healthcare Prof:

Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced that the European Commission has approved Cimzia®, for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). Cimzia (certolizumab pegol), is a PEGylated anti-TNFa (Tumor Necrosis Factor alpha). The product is currently being developed by UCB and was approved in the US in May 2009. Cimzia is one of several products which utilize Enzon's PEGylation technology, including Oncaspar®, Adagen®, PEGINTRON®, Macugen®, and Pegasys®.

"Our PEGylation technology continues to enable very important therapeutics like Cimzia, benefiting patients with a wide variety of diseases," said Jeffrey H. Buchalter, Enzon's president and chief executive officer.

Source
Enzon Pharmaceuticals, Inc.

View drug information on Cimzia; Macugen; Pegasys.

Additional
References
Citations

Article adapted by Medical News Today from original press release.
Visit our arthritis / rheumatology section for the latest news on this subject.

There are no references listed for this article.

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Enzon Pharmaceuticals, Inc.. "UCB's Cimzia(R), The Only PEGylated Anti-TNF, Approved In Europe." Medical News Today. MediLexicon, Intl., 8 Oct. 2009. Web.
12 Feb. 2012. <http://www.medicalnewstoday.com/releases/166590.php>

APA

Enzon Pharmaceuticals, Inc.. (2009, October 8). "UCB's Cimzia(R), The Only PEGylated Anti-TNF, Approved In Europe." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/166590.php.

Please note: If no author information is provided, the source is cited instead.

Rate this article:
(Hover over the stars then click to rate)

Patient / Public:

Health Professional:

Add Your Opinion

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Arthritis / Rheumatology

What is Rheumatoid Arthritis?

Rheumatoid arthritis, sometimes referred to as rheumatoid disease, is a chronic (long lasting), progressive and disabling autoimmune disease that causes inflammation (swelling) and pain in the joints, the tissue around the joints, and other organs in... Read more...

Follow Our Arthritis News On Twitter

Get the latest news for this category delivered straight to your Twitter account. Simply visit our Arthritis / Rheumatology Twitter account and select the 'follow' option.

Conditions Information

View list of all 'What Is...' articles »

Your Name:*
E-mail Address:*
Title For Opinion:*
Opinion:*

This is to help prevent SPAM submissions. Please enter the words exactly as they appear, including capital letters and punctuation.*